Skip to main content

REVIEW article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1498288
This article is part of the Research Topic The Pivotal Role of Cytokines in Autoimmune Diseases View all 7 articles

Revisiting the role of IL-27 in obesity-related metabolic diseases: Safeguard or perturbation?

Provisionally accepted
Jinyang An Jinyang An 1Donghua Fu Donghua Fu 2Ximei Chen Ximei Chen 3Conghui Guan Conghui Guan 1,4Lingling Li Lingling Li 1Jia Bai Jia Bai 1Haihong Lv Haihong Lv 1,4*
  • 1 The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China
  • 2 The People's Hospital of Yuzhong County, Lanzhou, Gansu, China
  • 3 ZhengZhou YiHe Hospital, Zhengzhou, Henan Province, China
  • 4 First Hospital of Lanzhou University, Lanzhou, China

The final, formatted version of the article will be published soon.

    The prevalence of metabolic diseases, such as obesity, has been steadily increasing in recent years, posing a significant threat to public health. Therefore, early identification and intervention play a crucial role. With the deepening understanding of the etiology of metabolic diseases, novel therapeutic targets are emerging for the treatment of obesity, lipid metabolism disorders, cardiovascular and cerebrovascular diseases, glucose metabolism disorders, and other related metabolic conditions. IL-27, as a multi-potent cytokine, holds great promise as a potential candidate target in this regard. This article provides a comprehensive review of the latest findings on IL-27 expression and signal transduction in the regulation of immune inflammatory cells, as well as its implications in obesity and other related metabolic diseases. Furthermore, it explores the potential of IL-27 as a novel therapeutic target for the treatment of obesity and metabolic disorders. Finally, an overview is presented on both the opportunities and challenges associated with targeting IL-27 for therapeutic interventions.

    Keywords: il-27, Obesity, Metabolic Diseases, Cardiovascular Diseases, abnormal glucose metabolism, Lipid metabolism disorder, immune inflammation, A New target

    Received: 18 Sep 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 An, Fu, Chen, Guan, Li, Bai and Lv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Haihong Lv, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.